View All Clinical Trials

Clinical Trials

View All Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "SEE DETAILS" button. Or start a new search.

No search term entered. 363 results shown below.
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
Complete title: A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination with G-CSF, Cladribine, Cytarabine and Mitoxantrone (GCLAM) for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm

Principal Investigator: Roland Walter, MD

Study Number: 10000

Phase: I/II



Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
Complete title: A Multi-Center Randomized Phase II Study of Nivolumab in Combination with Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer [CA209-9FC]

Principal Investigator: David Zhen

Study Number: 10018

Phase: II



The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors
Complete title: The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors

Principal Investigator: Kathryn Pennington

Study Number: 10045

Phase: N/A



Resistance Training Program and Cardiovascular Exercise in Increasing Muscle Mass in Adolescent and Young Adult Stem Cell Transplant Survivors
Complete title: Pilot Study of a Resistance Training Intervention in Adolescent and Young Adult Hematopoietic Cell Transplant Survivors

Principal Investigator: Tyler Ketterl

Study Number: 10046

Phase: Pilot



Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders
Complete title: HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning with Low-dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide

Principal Investigator: Lauri Burroughs, MD

Study Number: 2032.00

Phase: II



Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Complete title: Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen

Principal Investigator: Lauri Burroughs, MD

Study Number: 2256.00

Phase: II



High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Complete title: A Phase II Trial of High-dose 90Y-Ibritumomab Tiuxetan (anti-CD20) followed by Fludarabine and Low-dose Total Body Irradiation and HLA-matched Allogeneic Hematopoietic Transplantation for Patients with Relapsed or Refractory Aggressive B-cell Lymphoma

Principal Investigator: Ajay Gopal, MD

Study Number: 2398.00

Phase: II



Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Complete title: Phase I/II Study of Adoptive Immunotherapy with Virus Specific CD8+ T Cells that have been Transduced to Express a WT1-Specific T Cell Receptor for Patients with Relapsed AML

Principal Investigator: Daniel Egan

Study Number: 2498.00

Phase: I/II



Scleroderma Treatment with Autologous Transplant (STAT) Study
Complete title: A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis

Principal Investigator: George Georges, MD

Study Number: 2533.00

Phase: II



Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)
Complete title: Initial Cytoreductive Therapy for Myelodysplastic Syndrome prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)

Principal Investigator: Bart Scott, MD

Study Number: 2661.00

Phase: II



American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)
Complete title: A Randomized, Controlled Trial Evaluating the Safety and Efficacy of Tranexamic Acid in Patients with Hematologic Malignancies and Severe Thrombocytopenia - A-TREAT: AmericanTrial Using Tranexamic Acid Therapy in Thrombocytopenia

Principal Investigator: Terry Gernsheimer, MD

Study Number: 50701

Phase: III



MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
Complete title: MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix

Principal Investigator: Nina Mayr, MD

Study Number: 8118

Phase: N/A



Web-Delivered Acceptance & Commitment Therapy for Smokers With Bipolar Disorder (WebQuit Plus)
Complete title: Web-Delivered Acceptance & Commitment Therapy for Smokers with Bipolar Disorder

Principal Investigator: Jaimee Heffner

Study Number: 8363

Phase: N/A



Together We STRIDE (Strategizing Together Relevant Interventions for Diet and Exercise)
Complete title: Together We STRIDE

Principal Investigator: Linda Ko

Study Number: 8417

Phase: II



Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia
Complete title: Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia

Principal Investigator: Lauri Burroughs, MD

Study Number: 8508

Phase: Pilot



High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients
Complete title: High vs. Standard Dose Flu Vaccine Stem Cell Transplant Recipients

Principal Investigator: Steven Pergam, MD

Study Number: 8583

Phase: II



A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma
Complete title: A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

Principal Investigator: Andrei Shustov, MD

Study Number: 9023

Phase: II



JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
Complete title: JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study

Principal Investigator: Rachel Salit

Study Number: 9033

Phase: II



Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)
Complete title: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients with Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Principal Investigator: Ajay Gopal, MD

Study Number: 9111

Phase: I/II



Allo vs. Hypomethylating/Best Supportive Care in MDS
Complete title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome

Principal Investigator: Bart Scott, MD

Study Number: 9129

Phase: III



Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Complete title: A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients

Principal Investigator: Nora Disis, MD

Study Number: 9140

Phase: I



Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
Complete title: Prevention of Bone Loss after Pediatric Hematopoietic Cell Transplantation

Principal Investigator: K.Scott Baker

Study Number: 9223

Phase: II



Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
Complete title: Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy after Autologous Transplant for Treating Multiple Myeloma

Principal Investigator: Leona Holmberg, MD, PhD

Study Number: 9266

Phase: II



Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer
Complete title: A Phase I/II Trial of Concurrent Chemohormonal therapy using Enzalutamide (MDV-3100) and Cabazitaxel in Patients with Metastatic Castration Resistant Prostate Cancer

Principal Investigator: Heather Cheng

Study Number: 9279

Phase: I/II



Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia
Complete title: Phase I/II study of Autologous (Central Memory / Naive) CD8+ T cells that have been Transduced to Express a WT1-specific T cell Receptor for Treatment of AML

Principal Investigator: Daniel Egan

Study Number: 9296

Phase: I/II



Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL)
Complete title: PARTIQol: Prostate Advance Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

Principal Investigator: Jing Zeng

Study Number: 9328

Phase: III



Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants (LVXSCID-ND)
Complete title: A Pilot Feasibility Study of Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Using a Self-Inactivating Lentiviral Vector to Transduce Autologous CD34+ Hematopoietic Cells

Principal Investigator: Aleksandra Petrovic

Study Number: 9356

Phase: Pilot



Diet and Exercise Program in Promoting Weight Loss and Improving Health in Patients With Low- or Low-Intermediate-Risk Prostate Cancer (PALS)
Complete title: PALS: Prostate Cancer Active Lifestyle Study

Principal Investigator: Jonathan Wright

Study Number: 9369

Phase: N/A



Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
Complete title: A Pilot Study of Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway

Principal Investigator: Heather Cheng

Study Number: 9381

Phase: Pilot



Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Complete title: A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer: (Rapamycin inhibition of DDSP [RID])

Principal Investigator: Robert Montgomery, MD

Study Number: 9388

Phase: I/II



JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Complete title: A Phase 1b Study of JCAR014, Autologous T cells Engineered to Express a CD19-specific Chimeric Antigen Receptor, in Combination with Durvalumab (MEDI4736) for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Principal Investigator: Cameron Turtle, PhD, MBBS

Study Number: 9457

Phase: I



Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
Complete title: A Phase II Study of Anti-PD-1 Antibody (MK-3475; pembrolizumab) for the Treatment of Minimal Residual Disease in Adults with Acute Lymphoblastic Leukemia

Principal Investigator: Ryan Cassaday

Study Number: 9458

Phase: II



Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
Complete title: A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined with Brentuximab Vedotin for Front-Line Treatment of ALK-positive Anaplastic Large Cell Lymphoma

Principal Investigator: Andrei Shustov, MD

Study Number: 9522

Phase: I/II



Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
Complete title: A Feasibility Study of 'Early' Allogenic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasm

Principal Investigator: Mary-Elizabeth Percival

Study Number: 9567

Phase: Pilot



Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
Complete title: A Phase 2 Study of Apalutamide in Active Surveillance Patients

Principal Investigator: Michael Schweizer

Study Number: 9582

Phase: II



FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging
Complete title: Personalized Radiation Therapy through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)

Principal Investigator: Jing Zeng

Study Number: 9599

Phase: II



Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Complete title: A Phase I Trial of Interleukin-2 and Pembrolizumab (MK-3475) Combination Therapy for Patients with Advanced Renal Cell Carcinoma

Principal Investigator: Scott Tykodi, MD

Study Number: 9611

Phase: I



CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer
Complete title: Evaluation of CT Perfusion Parameters as a Potential Biomarker for Pancreatic Cancer

Principal Investigator: Ryan O'Malley

Study Number: 9625

Phase: Pilot



Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission (WOKVAC)
Complete title: A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients with Breast Cancer

Principal Investigator: Nora Disis, MD

Study Number: 9626

Phase: I



Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
Complete title: Functional Liver Imaging with Sulfur Colloid SPECT/CT in Primary and Metastatic Liver Cancer Patients Receiving Liver-Directed Treatment: A Pilot Study

Principal Investigator: Smith Apisarnthanarax

Study Number: 9646

Phase: Pilot



Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Complete title: Phase II Window Study of Pembrolizumab in Untreated B-cell Non-Hodgkin Lymphoproliferative Diseases

Principal Investigator: Ajay Gopal, MD

Study Number: 9647

Phase: II



INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer (INTERVAL)
Complete title: The GAP4 Study: INTense Exercise foR surVivAL among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL - MCRPC): A Multicenter, Randomized, Controlled Phase III Study

Principal Investigator: Jonathan Wright

Study Number: 9665

Phase: III



Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
Complete title: Pragmatic Phase III Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

Principal Investigator: Li-Ming Fang

Study Number: 9701

Phase: III



Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Complete title: A Response-Adapted Clinical Trial of Weekly Carfilzomib with or without Rituximab for Waldenstrom's Macroglobulinemia and Marginal Zone Lymphoma

Principal Investigator: Stephen Smith

Study Number: 9702

Phase: II



A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Complete title: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Principal Investigator: Mazyar Shadman

Study Number: 9738

Phase: I/II



Endocrine Response in Women With Invasive Lobular Breast Cancer
Complete title: A Trial of Endocrine Response in Women with Invasive Lobular Breast Cancer

Principal Investigator: Hannah Linden, MD

Study Number: 9743

Phase: II



Previous Study | Return to List | Next Study Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Complete title: CLBH589DUS108T: Panobinostat with Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation with In Vitro Chemosensitivity Testing

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 9757

Phase: II



Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm
Complete title: Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults with Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study

Principal Investigator: Anna Halpern

Study Number: 9759

Phase: II



Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma
Complete title: A Phase I Study of Adoptive Immunotherapy for Advanced B-cell Maturation Antigen (BCMA)+ Multiple Myeloma with Autologous CD4+ and CD8+ T cells Engineered to Express a BCMA-specific Chimeric Antigen Receptor

Principal Investigator: Damian Green, MD

Study Number: 9762

Phase: I



Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia
Complete title: Autologous Transplant as Treatment for Favorable or Intermediate Risk MRD-Negative AML Patients after Initial Induction Therapy

Principal Investigator: Leona Holmberg, MD, PhD

Study Number: 9784

Phase: II



HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions
Complete title: HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial

Principal Investigator: Anna Wald, MD, MPH

Study Number: 9790

Phase: IV



TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
Complete title: TraceIT(TM) Hydrogel Tissue Marker for Patients Receiving Definitive Chemoradiation for Bladder Cancer

Principal Investigator: Jing Zeng

Study Number: 9798

Phase: Pilot



Adjuvant Avelumab in Merkel Cell Cancer (ADAM)
Complete title: A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases

Principal Investigator: Shailender Bhatia, MD

Study Number: 9820

Phase: III



Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma
Complete title: A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients with High-Risk Classical Hodgkin Lymphoma

Principal Investigator: Leona Holmberg, MD, PhD

Study Number: 9826

Phase: II



Genetic Testing for Men With Metastatic Prostate Cancer (GENTleMEN)
Complete title: GENTleMEN: GENetic Testing for MEN with metastatic prostate cancer

Principal Investigator: Heather Cheng

Study Number: 9831

Phase: N/A



Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
Complete title: PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin followed by Maintenance Rucaparib in Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with Homologous Recombination DNA Repair Deficiency

Principal Investigator: Heather Cheng

Study Number: 9841

Phase: II



Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma
Complete title: A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin plus Nivolumab, Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma

Principal Investigator: Stephen Smith

Study Number: 9844

Phase: II



Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
Complete title: Phase I/IIA Study of the Oral 5-Azacitidine in Combination with the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients with T-Cell Lymphoma of Germinal Center-Derived B-Cell Lymphoma

Principal Investigator: Andrei Shustov, MD

Study Number: 9871

Phase: I/II



Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer
Complete title: Utilizing Multiomic Advanced Diagnostics to Identify CDK4/6 inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer

Principal Investigator: Rachel Yung

Study Number: 9873

Phase: N/A



Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Complete title: Durvalumab (MEDI4376), Tremelimumab and Palliative Hypofractionated Radiation (SBRT) in patients with recurrent/metastatic squamous cell carcinomas of the head and neck previously treated with immune checkpoint inhibitors

Principal Investigator: Cristina Rodriguez

Study Number: 9881

Phase: I/II



Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
Complete title: A Pilot Study of Pembrolizumab in Combination with Y90 Radioembolization in Subjects with Poor Prognosis Hepatocellular Carcinoma with Preserved Liver Function

Principal Investigator: William Harris

Study Number: 9913

Phase: Pilot



BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma
Complete title: A Phase I Study of B-cell Maturation Antigen (BCMA)-specific Chimeric Antigen Receptor T cells in Combination with LY3039478 (JSMD194), a Small Molecule Inhibitor of Gamma Secretase, in Patients with Relapsed or Persistent Multiple Myeloma

Principal Investigator: Andrew Cowan

Study Number: 9952

Phase: I



Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease
Complete title: Randomized Feasibility Study of Discontinuation versus Continuation of Immunosuppressive Therapy (IST) in Patients with Chronic Graft Versus Host Disease (GVHD)

Principal Investigator: Merav Bar, MD

Study Number: 9962

Phase: II



Positive Psychology Intervention to Improve Quality of Life in Stem Cell Transplant Survivors and Their Caregivers
Complete title: Feasibility of a Positive Psychology Intervention for Hematopoietic Cell Transplant Survivors to Improve Quality of Life

Principal Investigator: Stephanie Lee, MD, MPH

Study Number: 9969

Phase: Pilot



Pembrolizumab in Refractory Metastatic Anal Cancer
Complete title: A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal Cancer

Principal Investigator: Andrew Coveler, MD

Study Number: 9974

Phase: II



Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer
Complete title: Bipolar Androgen Therapy Plus Olaparib in Patient with Castration-Resistant Prostate Cancer

Principal Investigator: Michael Schweizer

Study Number: 9984

Phase: II



Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer
Complete title: Open-Label, Pilot Study of Olaparib as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer

Principal Investigator: Robert Montgomery, MD

Study Number: 9985

Phase: II



Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors (PACT)
Complete title: Physical Activity after Cancer Treatment (PACT): Pilot Study Randomized Controlled Trial of Exercise in Stage II-III Breast Cancer Survivors

Principal Investigator: Karen Syrjala, PhD

Study Number: 9988

Phase: Pilot



Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy
Complete title: The Evaluation of a Work Intervention to Facilitate Work Maintenance or Re-entry to the Workforce for Breast Cancer Patients

Principal Investigator: Rachel Yung

Study Number: 9993

Phase: Pilot



Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
Complete title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Principal Investigator: Janice Kim, MD

Study Number: A011202

Phase: III



Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE)
Complete title: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy

Principal Investigator: Rachel Yung

Study Number: A221405

Phase: N/A



Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
Complete title: Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: (see comment for full title)

Principal Investigator: Julie Park, MD

Study Number: ENCIT-01

Phase: I



Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
Complete title: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Principal Investigator: Heidi Gray, MD

Study Number: GOG 0724/ RTOG 0724

Phase: III



Health Effects After Leukemia Research Study #2 (HEAL-2)

Principal Investigator: Eric Chow, MD

Study Number: HEAL-2

Phase: NA



A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia
Complete title: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia

Principal Investigator: Rebecca Gardner, MD

Study Number: PLAT-02

Phase: I/II



Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
Complete title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-03: A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia

Principal Investigator: Colleen Annesley, MD

Study Number: PLAT-03

Phase: Pilot



A Phase 1 Study of CD22 CAR T-Cell Immunotherapy for CD22+ Leukemia (PLAT-04)
Complete title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22-CAR T Cell Immunotherapy for CD22+ Leukemia

Principal Investigator: Corinne Summers

Study Number: PLAT-04

Phase: I



Engaging School and Family in Navajo Gardening for Health
Complete title: Engaging School and Family in Navajo Gardening for Health

Principal Investigator: Shirley Beresford, PhD

Study Number: RG1001447

Phase: N/A



Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study) (Quit2Heal)
Complete title: Pilot Randomized Trial of a Smartphone Smoking Cessation Intervention for Cancer Patients

Principal Investigator: Jonathan Bricker

Study Number: RG1001682

Phase: Pilot



Pilot Trial of the First Conversational Agent for Smoking Cessation (QuitBot) (QuitBot)
Complete title: Pilot Randomized Trial of a Coversational Agent Smoking Cessation Intervention (QuitBot Study)

Principal Investigator: Jonathan Bricker

Study Number: RG1001766



Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Complete title: SC-4002, An Open Label, Expanded Access Protocol Using 131I - Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Principal Investigator: Navin Pinto, MD

Study Number: SC-4002



The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
Complete title: SC-4006, Multicenter Cohort Study To Evaluate Outcomes after Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults with Recurrent, Refractory...

Principal Investigator: Navin Pinto, MD

Study Number: SC-4006

Phase: N/A



ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma
Complete title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib, and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma

Principal Investigator: Doug Hawkins, MD

Study Number: SC-6015

Phase: I



A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Complete title: A Pilot Study Evaluating the use of the mTOR Inhibitor Sirolimus in Children and Young Adults with Desmoid-Type Fibromatosis

Principal Investigator: Doug Hawkins, MD

Study Number: SC-6016

Phase: Pilot



Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
Complete title: SC-9002: A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paciltaxel, and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoeitic Stem Cell Rescue (AuHSCR) for patients with…

Principal Investigator: Sarah Leary

Study Number: SC-9002

Phase: II



Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Complete title: Pilot Study of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children with Wnt Positive Standard Risk Medulloblastoma

Principal Investigator: Sarah Leary

Study Number: SC-9008

Phase: Pilot



Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT)
Complete title: PHASE II STUDY OF ALISERTIB AS A SINGLE AGENT IN RECURRENT AND REFRACTORY CENTRAL NERVOUS SYSTEM ATYPICAL TERATOID RHABDOID TUMORS (ATRT) AND EXTRA-CNS MALIGNANT RHABDOID TUMORS (MRT) AND IN COMBINATION THERAPY IN NEWLY DIAGNOSED ATRT (SJATRT)

Principal Investigator: Sarah Leary

Study Number: SC-9010

Phase: II



Evaluation of microRNAs as novel markers of cardiotoxicity in children undergoing anthracycline therapy for pediatric cancer

Principal Investigator: Kasey Leger, MD

Study Number: SC-B610

Phase: N/A



Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications
Complete title: Defining the Molecular Profile of Breast Cancer in Uganda and its Clinical Implications

Principal Investigator: Manoj Menon

Study Number: U025

Phase: I



SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart
Complete title: SmART Heart: Study of mHealth Apps to Reduce cancer-Treatment effects on the Heart

Principal Investigator: Eric Chow, MD

Study Number: 10037

Phase: N/A



Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen

Principal Investigator: Ann Dahlberg

Study Number: 2010.00

Phase: II



A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Complete title: A blanket protocol to study oral regorafenib in patients with selected sarcoma subtypes

Principal Investigator: Elizabeth Loggers

Study Number: 20132286

Phase: II



Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation - A Multi-Center Trial

Principal Investigator: Brenda Sandmaier, MD

Study Number: 2206.00

Phase: II



Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
Complete title: High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases

Principal Investigator: George Georges, MD

Study Number: 2260.00

Phase: II



Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant
Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen

Principal Investigator: Filippo Milano

Study Number: 2275.00

Phase: II



Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Principal Investigator: Rachel Salit

Study Number: 2372.00

Phase: II



A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Complete title: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications

Principal Investigator: Ann Dahlberg

Study Number: 2531.00

Phase: N/A



Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Complete title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor

Principal Investigator: David Maloney, MD, PhD

Study Number: 2639.00

Phase: I/II



Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Complete title: A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD

Principal Investigator: Marie Bleakley, MD

Study Number: 2684.00

Phase: II



Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
Complete title: Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

Principal Investigator: Robert Montgomery, MD

Study Number: 6932

Phase: N/A



Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma
Complete title: A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients with CD30+ Malignancies Refractory to Every 3 Week Brentuximab Vedotin

Principal Investigator: Ajay Gopal, MD

Study Number: 7808

Phase: II



Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma
Complete title: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with lp/19q Co-deleted Anaplastic Glioma or Low Grade Glioma

Principal Investigator: George Laramore, MD, PhD

Study Number: 8078

Phase: III



Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
Complete title: Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination with Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers

Principal Investigator: Gabriela Chiorean

Study Number: 9078

Phase: I



Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy
Complete title: Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study

Principal Investigator: Anna Halpern

Study Number: 9105

Phase: Pilot



Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma
Complete title: A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma

Principal Investigator: Ajay Gopal, MD

Study Number: 9107

Phase: Pilot



Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies
Complete title: Evaluation of Pretargeted anti-CD20 Radioimmunotherapy Combined with BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-cell Malignancies

Principal Investigator: Ajay Gopal, MD

Study Number: 9189

Phase: I



HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)
Complete title: A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine

Principal Investigator: K.Scott Baker

Study Number: 9213

Phase: II



High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
Complete title: Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 9226

Phase: Pilot



Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Complete title: Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies with Defined Subsets of Autologous T cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor

Principal Investigator: David Maloney, MD, PhD

Study Number: 9330

Phase: I



huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
Complete title: A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-targeted Chimeric Antigen Receptor (CAR)-Modified T cells Bearing a Human Binding Domain, in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia

Principal Investigator: Cameron Turtle, PhD, MBBS

Study Number: 9364

Phase: I



Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome
Complete title: A Phase II Study of Deferasirox in Patients with Myelodysplastic Syndromes who are Anemic with Iron Overload

Principal Investigator: Bart Scott, MD

Study Number: 9422

Phase: II



Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Complete title: Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects with Relapsed Follicular and Diffuse Large B-Cell Lymphoma

Principal Investigator: Stephen Smith

Study Number: 9469

Phase: II



Enhancing Connections Program in Improving Communication Between Patients With Incurable Cancer and Their Children
Complete title: The Enhancing Connections Program in Palliative Care: Taking Care of the Children

Principal Investigator: Frances Lewis, PhD

Study Number: 9480

Phase: Pilot



Filgrastim, Cladribine, Cytarabine and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Complete title: Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD status: A Phase 1/2 Study

Principal Investigator: Anna Halpern

Study Number: 9510

Phase: I/II



Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
Complete title: A Window Study of Ixazomib in Untreated Indolent B-NHL

Principal Investigator: Ajay Gopal, MD

Study Number: 9571

Phase: II



211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
Complete title: A Study Evaluating Escalating Doses of 211At-labeled anti-CD45 MAb BC8-B10 (211At-BC8-B10) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)

Principal Investigator: Brenda Sandmaier, MD

Study Number: 9595

Phase: I/II



A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
Complete title: A Phase I/ II Study of chemo radiation plus the Anti-PD-1 Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma

Principal Investigator: Cristina Rodriguez

Study Number: 9649

Phase: I/II



Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Complete title: ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy with concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma

Principal Investigator: Ramesh Rengan

Study Number: 9712

Phase: II



HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Complete title: Phase I Study of Adoptive Immunotherapy with CD8+ and CD4+ Memory T cells Transduced to Express an HA-1-specific T cell Receptor (TCR) for Children and Adults with Recurrent Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)

Principal Investigator: Marie Bleakley, MD

Study Number: 9716

Phase: I



Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Complete title: Anti-PD-1 Therapy in Combination with Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Principal Investigator: John Liao

Study Number: 9740

Phase: I/II



IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
Complete title: A Phase II Study of Concurrent IGFBP-2 Vaccination and Neoadjuvant Chemotherapy to Increase the Rate of Pathologic Complete Response at the Time of Cytoreductive Surgery

Principal Investigator: John Liao

Study Number: 9760

Phase: II



Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Complete title: A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults with Acute Lymphoblastic Leukemia/Lymphoma

Principal Investigator: Ryan Cassaday

Study Number: 9770

Phase: II



Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Complete title: Management of Venous Thromboembolic Events (VTE) in Patients with Hematologic Disorders and Treatment-Induced Thrombocytopenia: a Pilot Study

Principal Investigator: David Garcia

Study Number: 9799

Phase: II



Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Complete title: A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus combined with MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis after HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation using Nonmyeloablative or Reduced Intensity Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial

Principal Investigator: Masumi Ueda

Study Number: 9816

Phase: II



Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant
Complete title: INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-Management Program for Survivors after Hematopoietic Cell Transplantation

Principal Investigator: Karen Syrjala, PhD

Study Number: 9819

Phase: N/A



Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma
Complete title: A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination with Pazopanib for Refractory Soft Tissue Sarcoma.

Principal Investigator: Lee Cranmer

Study Number: 9843

Phase: II



Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Complete title: Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita/telomere disease

Principal Investigator: Lauri Burroughs, MD

Study Number: 9861

Phase: II



High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Complete title: Individualized Treatment for Relapsed/Refractory Multiple Myeloma Based on High Throughput Drug Sensitivity and Genomics Data

Principal Investigator: Andrew Cowan

Study Number: 9944

Phase: N/A



WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
Complete title: ADVL1312, A PHASE 1/2 STUDY OF MK-1775 (AZD1775, IND# 121422) IN COMBINATION WITH ORAL IRINOTECAN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SOLID TUMORS

Principal Investigator: Julie Park, MD

Study Number: ADVL1312

Phase: I/II



HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors
Complete title: BrainChild-01, Phase 1 Study of HER2-specific CAR T Cell Locoregional Immunotherapy for HER2+ Recurrent/Refractory Pediatric Brain Tumors

Principal Investigator: Nicholas Vitanza, MD

Study Number: BrainChild-01

Phase: I



Long Term Follow-Up of Patients Previously Entered on Children's Hospital and Regional Medical Center Hematology/Oncology Clinical Trials

Principal Investigator: K.Scott Baker

Study Number: CHMC-L001



A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)
Complete title: A Phase I Study of Ribociclib and Everolimus following radiation therapy in Children with Newly Diagnosed non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ biopsied DIPG and High Grade Gliomas (HGG)

Principal Investigator: Sarah Leary

Study Number: CONNECT1701

Phase: I



NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Complete title: Molecular Analysis for Therapy Choice (MATCH)

Principal Investigator: Fred Appelbaum, MD

Study Number: EAY131

Phase: II



A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma (PLAT-05)
Complete title: Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22-CAR T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma

Principal Investigator: Rebecca Gardner, MD

Study Number: PLAT-05

Phase: I



Communicating Health Information and Improving Coordination With Primary Care (CHIIP)
Complete title: Improving Treatment of Cardiocascular Risk Factors in Childhood Cancer Survivors (CHIIP Study - Communicating Health Information and Improving Coordination with Primary Care)

Principal Investigator: Eric Chow, MD

Study Number: RG1001538

Phase: II/III



Previous Study | Return to List | Next Study A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL
Complete title: A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL and Lymphoblastic Lymphoma

Principal Investigator: Colleen Annesley, MD

Study Number: SC-2028

Phase: Pilot



Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Complete title: PANAML: A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination with Fludarabine and Cytarabine in Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Principal Investigator: Todd Cooper

Study Number: SC-2029

Phase: I



Prospective Blood Collection for Local Immunotherapy Pre-Clinical Studies

Principal Investigator: Rebecca Gardner, MD

Study Number: SC-B801



Resilience in Serious Illness: a pilot feasibility study of the Promoting Resilience in Stress Management (PRISM) Intervention

Principal Investigator: Abby Rosenberg

Study Number: SC-N108



The Promoting Resilience in Stress Management (PRISM) Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
Complete title: The Promoting Resilience in Stress Management (PRISM) Intervention: a multi-site randomized controlled trial for Adolescents and Young Adults with advanced cancer

Principal Investigator: Abby Rosenberg

Study Number: SC-N128

Phase: N/A



Hypospadias, Indescended Testis, and Testicular Tumors: A Data and Specimen Banking Pilot Study

Principal Investigator: Margarett Shnorhavorian

Study Number: SCH-HUT-1



EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Complete title: PHASE I STUDY OF EGFR806 CAR T-CELL IMMUNOTHERAPY FOR RECURRENT/REFRACTORY SOLID TUMORS IN CHILDREN AND YOUNG ADULTS

Principal Investigator: Catherine Albert, MD

Study Number: STRIvE-01

Phase: I



S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)
Complete title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer

Principal Investigator: Julie Gralow, MD

Study Number: 9174

Phase: III



Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery
Complete title: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Principal Investigator: Gabriela Chiorean

Study Number: 9412

Phase: II/III



FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy
Complete title: [F18] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer

Principal Investigator: Hannah Linden, MD

Study Number: 9594

Phase: II



Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) (CHAMP)
Complete title: Optimizing Haploidentical Aplastic Anemia Transplantation (CHAMP)

Principal Investigator: Kanwaldeep Mallhi

Study Number: 9818

Phase: II



Haploidentical Bone Marrow Transplantation in Sickle Cell Patients
Complete title: Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease

Principal Investigator: Kanwaldeep Mallhi

Study Number: 9867

Phase: II



A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Complete title: A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML

Principal Investigator: Masumi Ueda

Study Number: 9883

Phase: III



Breast Cancer WEight Loss Study (BWEL Study)
Complete title: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

Principal Investigator: Julie Gralow, MD

Study Number: A011401

Phase: III



Aspirin in Preventing Recurrence of Cancer in Patients With Node Positive HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
Complete title: A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

Principal Investigator: Julie Gralow, MD

Study Number: A011502

Phase: III



Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Complete title: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Principal Investigator: Lynne Taylor, MD

Study Number: A071601

Phase: II



Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Complete title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Principal Investigator: Rafael Santana-Davila

Study Number: A151216

Phase: III



Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Complete title: AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum

Principal Investigator: Doug Hawkins, MD

Study Number: AALL1131

Phase: III



Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Complete title: AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Principal Investigator: Kasey Leger, MD

Study Number: AALL1231

Phase: III



Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Complete title: AALL1331 Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Principal Investigator: Rebecca Gardner, MD

Study Number: AALL1331

Phase: III



A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Complete title: AALL1521 INCB 18424-269 A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children with De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Principal Investigator: Colleen Annesley, MD

Study Number: AALL1521

Phase: II



Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Complete title: ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years

Principal Investigator: Doug Hawkins, MD

Study Number: ACNS0831

Phase: III



Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Complete title: ADVL1212, A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)

Principal Investigator: Julie Park, MD

Study Number: ADVL1212

Phase: I



Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

Principal Investigator: Julie Park, MD

Study Number: ADVL1412

Phase: I/II



Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Complete title: ADVL1521, A Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Principal Investigator: Todd Cooper

Study Number: ADVL1521

Phase: II



VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors
Complete title: ADVL1614, A Phase 1/2 Study of VX15/2503 (IND# 136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors

Principal Investigator: Julie Park, MD

Study Number: ADVL1614

Phase: I



Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Complete title: Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Principal Investigator: Doug Hawkins, MD

Study Number: AHEP1531

Phase: II/III



A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment (CheckMate 744)
Complete title: Risk adapted, response based Phase 2 trial of nivolumab and brentuximab vedotin followed by brentuximab vedotin and bendamustine for pediatric and young adults with relapsed or refractory CD30 positive classic Hodgkin lymphoma

Principal Investigator: Kasey Leger, MD

Study Number: AHOD1721

Phase: II



Neuropsychological and Behavioral Testing in Younger Patients With Cancer
Complete title: ALTE07C1, Neuropyschological, Social, Emotional and Behavioral Outcomes in Children with Cancer

Principal Investigator: Doug Hawkins, MD

Study Number: ALTE07C1

Phase: N/A



Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Complete title: ANBL1531: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)

Principal Investigator: Doug Hawkins, MD

Study Number: ANBL1531

Phase: III



Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Complete title: ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)

Principal Investigator: Rebecca Gardner, MD

Study Number: ANHL12P1

Phase: II



Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions
Complete title: APEC1621 NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF LOXO-101 (LAROTRECTINIB) IN PATIENTS WITH TUMORS HARBORING ACTIONABLE NTRK FUSIONS

Principal Investigator: Navin Pinto, MD

Study Number: APEC1621A

Phase: II



Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations
Complete title: APEC1621D, NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF LY3023414 IN PATIENTS WITH SOLID TUMORS

Principal Investigator: Navin Pinto, MD

Study Number: APEC1621D

Phase: II



Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations
Complete title: APEC1621G, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Vemurafenib in patients with tumors harboring BRAF V600 mutations

Principal Investigator: Navin Pinto, MD

Study Number: APEC1621G

Phase: II



Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes
Complete title: APEC1621H, NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of olaparib in patients with tumors harboring defects in DNA damage repair genes

Principal Investigator: Navin Pinto, MD

Study Number: APEC1621H

Phase: II



Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
Complete title: APEC1621I, NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)- PHASE 2 SUBPROTOCOL OF PALBOCICLIB IN PATIENTS WITH TUMORS HARBORING ACTIVATING ALTERATIONS IN CELL CYCLE GENES

Principal Investigator: Navin Pinto, MD

Study Number: APEC1621I

Phase: II



Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Complete title: APEC1621SC: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Principal Investigator: Navin Pinto, MD

Study Number: APEC1621SC

Phase: II



Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
Complete title: A Phase II Trial of MK-3475 (pembrolizumab) and Interferon Gamma 1-b Combination Immunotherapy in Patients with Previously Treated MF/SS

Principal Investigator: Mac Cheever

Study Number: CITN-13

Phase: II



A Single Arm Trial of Systemic and Subtenon Chemotherapy for Group C/D Intraocular Retinoblastoma

Principal Investigator: Doug Hawkins, MD

Study Number: COG ARET0231

Phase: III



Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Complete title: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission.

Principal Investigator: Brian Till, MD

Study Number: EA4151

Phase: III



Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL)
Complete title: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Principal Investigator: Rafael Santana-Davila

Study Number: EA5142

Phase: III



131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat (N2011-01)
Complete title: NANT 2011-01: STUDY OF SINGLE-AGENT 131I-MIBG, 131I-MIBG WITH VINCRISTINE AND IRINOTECAN, OR 131I-MIBG WITH VORINOSTAT FOR RESITANT/RELAPSED NEUROBLASTOMA

Principal Investigator: Navin Pinto, MD

Study Number: NANT 2011-01

Phase: II



Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Complete title: NANT 2011-04: A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma

Principal Investigator: Julie Park, MD

Study Number: NANT 2011-04

Phase: II



SF1126 for Patients With Relapsed or Refractory Neuroblastoma
Complete title: NANT 2014-01 Phase I Study of SF1126 for Patients with Relapsed or Refractory Neuroblastoma

Principal Investigator: Julie Park, MD

Study Number: NANT 2014-01

Phase: I



Study of Lorlatinib (PF-06463922)
Complete title: NANT 2015-02: PHASE 1/2 STUDY OF PF-06463922, AN ORAL SMALL MOLECULE INHIBITOR OF ALK/ROS1, FOR PATIENTS WITH ALK-DRIVEN RELAPSED OR REFRACTORY NEUROBLASTOMA

Principal Investigator: Navin Pinto, MD

Study Number: NANT 2015-02

Phase: I/II



MIBG With Dinutuximab
Complete title: NANT 2017-01: A Phase I study of 131I-MIBG with Dinutuximab for Relapsed or Refractory Neuroblastoma

Principal Investigator: Navin Pinto, MD

Study Number: NANT 2017-01

Phase: I



Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Complete title: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

Principal Investigator: Lia Halasz

Study Number: NRG-BN001

Phase: II



Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
Complete title: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Principal Investigator: Lia Halasz

Study Number: NRG-BN003

Phase: III



Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma
Complete title: A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas

Principal Investigator: Yolanda Tseng

Study Number: NRG-BN005

Phase: II



Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Complete title: A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Principal Investigator: Stacey Cohen

Study Number: NRG-GI002

Phase: II



Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
Complete title: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Principal Investigator: Janice Kim, MD

Study Number: NSABP B-51 / RTOG 1304

Phase: III



Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)
Complete title: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Principal Investigator: Jennifer Specht, MD

Study Number: NSABP B-55

Phase: III



Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Complete title: Phase I Study of CDK 4-6 Inhibitor PD-0332991 In Children With Recurrent, Progressive or Refractory Central Nervous System Tumors

Principal Investigator: Sarah Leary

Study Number: PBTC-042

Phase: I



PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Complete title: Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children

Principal Investigator: Sarah Leary

Study Number: PNOC001

Phase: II



Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas
Complete title: PNOC-002: Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E- or BRAF Ins T mutant Brain Tumors

Principal Investigator: Sarah Leary

Study Number: PNOC002

Phase: Pilot



Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT
Complete title: PNOC005: A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults with Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)

Principal Investigator: Sarah Leary

Study Number: PNOC005

Phase: I



H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas
Complete title: H3.3K27M Specific Peptide Vaccine Combined with poly-ICLC for the Treatment of newly diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as well as other newly diagnosed HLA-A2+ H3.3K27M Positive Gliomas

Principal Investigator: Sarah Leary

Study Number: PNOC007

Phase: I



Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Complete title: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Principal Investigator: Smith Apisarnthanarax

Study Number: RTOG 1112

Phase: III



Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Complete title: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC

Principal Investigator: Ramesh Rengan

Study Number: RTOG 1308

Phase: III



Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery
Complete title: A Randomized Phase II / Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Principal Investigator: Cristina Rodriguez

Study Number: RTOG-1008

Phase: II/III



Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Complete title: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer

Principal Investigator: Christina Baik

Study Number: S1400

Phase: II/III



Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer
Complete title: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Principal Investigator: Julie Gralow, MD

Study Number: S1416

Phase: II



Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
Complete title: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

Principal Investigator: Julie Gralow, MD

Study Number: S1418

Phase: III



Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Complete title: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Principal Investigator: Mazyar Shadman

Study Number: S1608

Phase: II



Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Complete title: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Principal Investigator: Heidi Gray, MD

Study Number: S1609

Phase: II



Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
Complete title: A FEASIBILITY TRIAL OF NEOADJUVANT CISPLATIN-PEMETREXED WITH ATEZOLIZUMAB IN COMBINATION AND IN MAINTENANCE FOR RESECTABLE MALIGNANT PLEURAL MESOTHELIOMA

Principal Investigator: Bernardo Goulart

Study Number: S1619

Phase: I



Exploring Genetic Changes In Pediatric Brain Tumors

Principal Investigator: Sarah Leary

Study Number: SC-B904

Phase: N/A



Study of ASTX727 vs IV Decitabine in MDS and CMML
Complete title: A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) versus IV Decitabine in Subjects with Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Principal Investigator: Joachim Deeg, MD

Study Number: 10029

Phase: III



An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant
Complete title: An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

Principal Investigator: Paul Carpenter, MD

Study Number: 10032

Phase: N/A



A Safety Study of SGN-LIV1A in Breast Cancer Patients
Complete title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer

Principal Investigator: Jennifer Specht, MD

Study Number: 20131069

Phase: I



AZD8186 First Time In Patient Ascending Dose Study
Complete title: A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB Mutated Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186

Principal Investigator: Tia Higano, MD

Study Number: 20131275

Phase: I



Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Complete title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumor

Principal Investigator: Shailender Bhatia, MD

Study Number: 20131294

Phase: I



An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Complete title: An Open-Label, Extension (Rollover) Study Of Vemurafenib in Patients with BRAFV600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol.

Principal Investigator: John Thompson, MD

Study Number: 20132215

Phase: III



Safety Study of Anti-LAG-3 in CLL, HL and NHL
Complete title: A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies

Principal Investigator: Ajay Gopal, MD

Study Number: 20132238

Phase: I



Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Complete title: A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn(R) (Pralatrexate) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)

Principal Investigator: Andrei Shustov, MD

Study Number: 20141037

Phase: II



Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
Complete title: A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA

Principal Investigator: Edward Libby

Study Number: 20142069

Phase: I



ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas
Complete title: A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Principal Investigator: Andrei Shustov, MD

Study Number: 20142126

Phase: I/II



Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer
Complete title: A Phase I Study of ES414 In Patients with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator: Tia Higano, MD

Study Number: 20142613

Phase: I



A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors
Complete title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 AS A SINGLE AGENT AND IN COMBINATION WITH PF-05082566 IN PATIENTS WITH SELECTEDLOCALLY ADVANCED OR METASTATIC CARCINOMAS

Principal Investigator: John Thompson, MD

Study Number: 20150061

Phase: I



Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
Complete title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies

Principal Investigator: Keith Eaton, MD, PhD

Study Number: 20150094

Phase: I



Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Complete title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

Principal Investigator: Michi Shinohara

Study Number: 20151086

Phase: III



Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas
Complete title: Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Principal Investigator: Andrei Shustov, MD

Study Number: 20151174

Phase: I/II



A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)
Complete title: A Phase I Study to Evaluate The Safety, PHarmacokinetics and PHarmacodynamics of Escalating Doses of a Vaccine-Based Immunotherapy Regimen (VBIR) for Prostate Cancer (PF-06753512)

Principal Investigator: Tia Higano, MD

Study Number: 20151318

Phase: I



A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
Complete title: A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

Principal Investigator: Laura Chow

Study Number: 20151522

Phase: I



A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma
Complete title: A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma

Principal Investigator: William Harris

Study Number: 20151721

Phase: I



A Dose-Finding Study of Folotyn® (Pralatrexate Injection) With Peripheral T-Cell Lymphoma (PTCL)
Complete title: A Phase 1, Dose-Finding Study of Folotyn(R) (Pralatrexate Injection) PLUS Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)

Principal Investigator: Andrei Shustov, MD

Study Number: 20151824

Phase: I



Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA)
Complete title: A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment

Principal Investigator: Lupe Salazar, MD

Study Number: 20151845

Phase: III



A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)
Complete title: Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-963558) In subjects with Virus-Positive and Virus-Negative Tumors

Principal Investigator: Shailender Bhatia, MD

Study Number: 20152209

Phase: I/II



Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)
Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Principal Investigator: Gabriela Chiorean

Study Number: 20152369

Phase: II



A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
Complete title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Principal Investigator: Andrew Coveler, MD

Study Number: 20152434

Phase: III



A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Complete title: A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY

Principal Investigator: Petros Grivas, MD, PhD

Study Number: 20152463

Phase: III



Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)
Complete title: A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Principal Investigator: Jonathan Wright

Study Number: 20152548

Phase: II



Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer (HER2CLIMB)
Complete title: Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

Principal Investigator: Jennifer Specht, MD

Study Number: 20152617

Phase: II



Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
Complete title: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Principal Investigator: John Thompson, MD

Study Number: 20152783

Phase: I



A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Complete title: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors

Principal Investigator: Elizabeth Swisher, MD

Study Number: 20160056

Phase: I



The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma
Complete title: The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma, A Multicenter, Prospective Blinded Pivotal Study

Principal Investigator: Jonathan Wright

Study Number: 20160470

Phase: N/A



A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors
Complete title: A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors

Principal Investigator: Gabriela Chiorean

Study Number: 20160524

Phase: I



Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577)
Complete title: BMS CA209-577 (CheckMate 577): A Randomized, Multicenter, Double Blind, Phase III Study of Nivolumab or Placebo in Subjects with Resected Lower Esophageal, or Gastroesophageal Junction Cancer

Principal Investigator: Veena Shankaran

Study Number: 20160534

Phase: III



A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Complete title: PHASE 1B STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND EITHER LETROZOLE OR FULVESTRANT IN WOMEN WITH METASTATIC OR LOCALLY ADVANCED/RECURRENT BREAST CANCER (MBC)

Principal Investigator: Jennifer Specht, MD

Study Number: 20160661

Phase: I



Safety and Efficacy Study in Recurrent Grade IV Glioma
Complete title: An Open-Label, Phase 1/2a Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma

Principal Investigator: Lynne Taylor, MD

Study Number: 20160816

Phase: I/II



Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors
Complete title: A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors

Principal Investigator: Scott Tykodi, MD

Study Number: 20160860

Phase: I/II



Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Complete title: A Phase 1b/2, Open-Label, Multicenter Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Principal Investigator: Cristina Rodriguez

Study Number: 20160938

Phase: I/II



Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)
Complete title: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

Principal Investigator: Ryan Lynch

Study Number: 20161033

Phase: II



A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)
Complete title: A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Principal Investigator: Laura Chow

Study Number: 20161065

Phase: II



Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)
Complete title: A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects with NTRK Fusion-Positive Tumors

Principal Investigator: Christina Baik

Study Number: 20161101

Phase: I/II



A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C)
Complete title: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Principal Investigator: Stacey Cohen

Study Number: 20161165

Phase: III



Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Complete title: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

Principal Investigator: Keith Eaton, MD, PhD

Study Number: 20161383

Phase: I/II



Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Complete title: A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

Principal Investigator: John Thompson, MD

Study Number: 20161740

Phase: I



Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL
Complete title: A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evalute the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion, 0.5%, for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sezary Syndrome (SS) Forms of Cutaneous T-Cell Lymphoma (CTCL)

Principal Investigator: Michi Shinohara

Study Number: 20161793

Phase: II/III



An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies (Galahad)
Complete title: A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Principal Investigator: Heather Cheng

Study Number: 20162044

Phase: II



Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC)
Complete title: A Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Principal Investigator: Scott Tykodi, MD

Study Number: 20162312

Phase: I/II



A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC)
Complete title: A Phase 2, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric)

Principal Investigator: Veena Shankaran

Study Number: 20162429

Phase: II



A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Complete title: Phase 1b, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589)

Principal Investigator: Jennifer Specht, MD

Study Number: 20162431

Phase: I



A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)
Complete title: A PHASE Ib STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ALONE OR INCOMBINATION WITH AN IMMUNOMODULATORY DRUG AND/OR DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA (RELAPSED/REFRACTORY AND POST-AUTOLOGOUS STEM CELL TRANSPLANTATION)

Principal Investigator: Edward Libby

Study Number: 20162520

Phase: I/II



A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Complete title: A phase 1, multicenter, open-label, dose-escalation study of SGN-2FF in patients with advanced solid tumors

Principal Investigator: Laura Chow

Study Number: 20162576

Phase: I



The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)
Complete title: A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel(TM) on Ablation of Upper Urinary Tract Urothelial Carcinoma

Principal Investigator: John Gore

Study Number: 20162686

Phase: III



Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy)
Complete title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation

Principal Investigator: William Harris

Study Number: 20162729

Phase: III



A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02)
Complete title: A Phase 1/2, Open-Label, Multicenter, Dose-Escalation and Dose Expansion Study of NKTR-214 and Anti-PD-L1 (Atezolizumab) or Anti-PD-1 (Nivolumab, Pembrolizumab) in Patients with Select Locally Advanced or Metastatic Solid Tumor Malignancies

Principal Investigator: Scott Tykodi, MD

Study Number: 20162818

Phase: I/II



A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Complete title: A Phase 2, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)

Principal Investigator: Scott Tykodi, MD

Study Number: 20162874

Phase: II



A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Complete title: A Phase 1 Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Principal Investigator: Michael Schweizer

Study Number: 20162882

Phase: I



Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)
Complete title: A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Principal Investigator: Elizabeth Swisher, MD

Study Number: 20162888

Phase: II



A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)
Complete title: A randomized phase 3 trial of TRC105 and Pazopanib versus Pazopanib alone in patients with advanced angiosarcoma

Principal Investigator: Lee Cranmer

Study Number: 20162889

Phase: III



Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE)
Complete title: A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy

Principal Investigator: Rafael Santana-Davila

Study Number: 20162925

Phase: III



Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Complete title: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)

Principal Investigator: Evan Yu, MD

Study Number: 20162991

Phase: I/II



A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)
Complete title: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IV OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER

Principal Investigator: Heidi Gray, MD

Study Number: 20170050

Phase: III



A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Complete title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Principal Investigator: Stephen Smith

Study Number: 20170154

Phase: III



A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN)
Complete title: ATTAIN (15-102-14/ NEKTAR) / A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine

Principal Investigator: Jennifer Specht, MD

Study Number: 20170164

Phase: III



Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Complete title: A PHASE 1/2A OPEN-LABEL, MULTI-DOSE, MULTI-CENTER ESCALATION AND EXPLORATORY STUDY OF CERDULATINIB (PRT062070) IN PATIENTS WITH RELAPSED/ REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/ SMALL LYMPHOCYTIC LYMPHOMA (SLL) OR B-CELL OR T-CELL NON-HODGKIN LYMPHOMA (NHL)

Principal Investigator: Stephen Smith

Study Number: 20170188

Phase: I/II



A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Complete title: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER

Principal Investigator: Christina Baik

Study Number: 20170224

Phase: III



A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma
Complete title: A Phase 1, Dose Escalation Study of ALX148 in Patients with Advanced Solid Tumors and Lymphoma

Principal Investigator: Laura Chow

Study Number: 20170279

Phase: I



Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
Complete title: A PHASE IB, OPEN-LABEL STUDY OF THESAFETY AND TOLERABILITY OF ATEZOLIZUMAB IN COMBINATION WITH RADIUM-223 DICHLORIDE IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER WHO HAVE PROGRESSED FOLLOWING TREATMENT WITH AN ANDROGEN PATHWAY INHIBITOR

Principal Investigator: Tia Higano, MD

Study Number: 20170291

Phase: I



Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Complete title: A Phase 1b Clinical Study of CWP232291 in Combination with Cytarabine in Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 20170427

Phase: I



NLA101 in Adults Receiving High Dose Chemotherapy for AML (LAUNCH)
Complete title: A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia

Principal Investigator: Mary-Elizabeth Percival

Study Number: 20170592

Phase: II



Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Complete title: A Phase 1/2 STudy Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

Principal Investigator: John Thompson, MD

Study Number: 20170627

Phase: I/II



TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Complete title: Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy

Principal Investigator: Ryan Lynch

Study Number: 20170668

Phase: II



A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Complete title: A Phase 1/1b Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15-15Ra)) alone and in Combination with PDR001 in Adults with Metastatic Cancers

Principal Investigator: John Thompson, MD

Study Number: 20170681

Phase: I



A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer
Complete title: A Phase I Dose Escalation Study, with Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients with Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer

Principal Investigator: Andrew Coveler, MD

Study Number: 20170696

Phase: I



An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab or Ipilimumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)
Complete title: A Phase 3, Randomized Study of Adjuvant Immunotherapy with Nivolumab Combined with Ipilimumab Versus Ipilimumab or Nivolumab Monotherapy after Complete Resection of Stage IIIb/c/d or Stage IV Melanoma

Principal Investigator: Shailender Bhatia, MD

Study Number: 20170952

Phase: III



A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Complete title: A Phase 2, Two-Cohort Study of INCB050465, a PI3Kd Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)

Principal Investigator: Stephen Smith

Study Number: 20170968

Phase: II



Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901)
Complete title: A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer

Principal Investigator: Eric Dean

Study Number: 20171048

Phase: III



ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Complete title: A Pivotal Trial of ARQ 087 in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Principal Investigator: William Harris

Study Number: 20171078

Phase: III



Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
Complete title: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma

Principal Investigator: Cristina Rodriguez

Study Number: 20171087

Phase: III



Study of REGN2810 in Adults With Cervical Cancer
Complete title: AN OPEN-LABEL, RANDOMIZED, PHASE 3 CLINICAL TRIAL OF REGN2810 VERSUS THERAPY OF INVESTIGATOR'S CHOICE CHEMOTHERAPY IN RECURRENT OR METASTATIC PLATINUM-REFRACTORY CERVICAL CARCINOMA

Principal Investigator: John Liao

Study Number: 20171128

Phase: III



Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Complete title: A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects with Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Principal Investigator: William Harris

Study Number: 20171201

Phase: I



A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
Complete title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBor D Alone in Newly Diagnosed Systemic AL Amyloidosis

Principal Investigator: Edward Libby

Study Number: 20171437

Phase: III



A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Complete title: A PHASE IA/IB OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF RO7198457 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS

Principal Investigator: Kit Wong

Study Number: 20171486

Phase: I



Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
Complete title: A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer

Principal Investigator: Hannah Linden, MD

Study Number: 20171553

Phase: I/II



A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)
Complete title: A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects with Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)

Principal Investigator: Terry Gernsheimer, MD

Study Number: 20171575

Phase: I



An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
Complete title: A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction with Progestin Therapy in Patients with Endometrial Carcinoma

Principal Investigator: Heidi Gray, MD

Study Number: 20171616

Phase: II



An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
Complete title: A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kd Inhibitor, in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Principal Investigator: Ryan Lynch

Study Number: 20172013

Phase: II



Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)
Complete title: A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) plus Binimetinib alone or the Combination of Pembrolizumab plus Chemotherapy with or without Binimetinib in Participants with Metastatic Colorectal Cancer (KEYNOTE-651)

Principal Investigator: Gabriela Chiorean

Study Number: 20172258

Phase: I



Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Complete title: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Niraparib Combined with Bevacizumab as Maintenance Treatment in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab (TESARO 3000-02-004)

Principal Investigator: Heidi Gray, MD

Study Number: 20172287

Phase: II



ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)
Complete title: A Phase 3 Randomized, Double-blind, Placebo-controlled Multicenter Study with an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients with Acute Hepatic Porphyrias (ENVISION-AHP)

Principal Investigator: Sioban Keel, MD

Study Number: 20172377

Phase: III



A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)
Complete title: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor (CPI) therapy

Principal Investigator: Evan Yu, MD

Study Number: 20172434

Phase: II



Phase 2 Study of Poziotinib in Patients With NSCLC With EGFR or HER2 Exon 20 Insertion Mutation
Complete title: A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)

Principal Investigator: Christina Baik

Study Number: 20172584

Phase: II



Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
Complete title: A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors

Principal Investigator: Christina Baik

Study Number: 20172740

Phase: I



Phase 1b Dose Escalation and Dose Expansion Trial of DV281 in Combination With an Approved Anti-PD-1 Inhibitor in Subjects With Advanced Non-Small Cell Lung Cancer
Complete title: Phase 1b Dose Escalation and Dose Expansion Trial of DV281 in Combination With an Approved Anti-PD-1 Inhibitor in Subjects With Advanced Non-Small Cell Lung Cancer

Principal Investigator: Laura Chow

Study Number: 20172849

Phase: I



Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer
Complete title: A Multicenter, Open-Label Study of LYC-55716 in Combination with Pembrolizumab in Adult Subjects with Metastatic Non-Small Cell Lung Cancer

Principal Investigator: Rafael Santana-Davila

Study Number: 20172938

Phase: I



A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Complete title: A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer: 14D-MC-JTJN

Principal Investigator: Heidi Gray, MD

Study Number: 20172944

Phase: II



Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer
Complete title: A Phase 1 with Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects with Recurrent or Refractory Solid Tumors

Principal Investigator: Kit Wong

Study Number: 20180001

Phase: I



A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (CheckMate 9DX)
Complete title: A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation

Principal Investigator: William Harris

Study Number: 20180156

Phase: III



A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma
Complete title: A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma

Principal Investigator: Andrew Cowan

Study Number: 20180308

Phase: III



Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)
Complete title: PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma

Principal Investigator: Andrew Coveler, MD

Study Number: 20180332

Phase: III



PCM-075 in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)
Complete title: A Phase 1b/2 Study of PCM-075 in Combination with Either Low-Dose Cytarabine or Decitabine in Subjects with Acute Myeloid Leukemia (AML)

Principal Investigator: Pamela Becker, MD, PhD

Study Number: 20180368

Phase: I/II



An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients with Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)

Principal Investigator: Lee Cranmer

Study Number: 20180686

Phase: III



Pembrolizumab Plus Epacadostat Alone or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-02/ECHO-306)
Complete title: A Randomized Phase 3 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Alone or with Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer

Principal Investigator: Renato Martins, MD, MPH

Study Number: 20180852

Phase: III



Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)
Complete title: ATLAS: A Phase 2, Open-label Study of Rucaparib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma

Principal Investigator: Petros Grivas, MD, PhD

Study Number: 20180915

Phase: II



Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma
Complete title: Phase 1 Study of ADI-PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies

Principal Investigator: Stacey Cohen

Study Number: 20180995

Phase: I



A Study to Assess the Efficacy of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN) 18.2 Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (Spotlight)
Complete title: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Principal Investigator: Veena Shankaran

Study Number: 20181168

Phase: III



A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Complete title: A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants with Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)

Principal Investigator: Edward Libby

Study Number: 20181184

Phase: II



An Open label, Phase I/II study to evaluate the safety and efficacy of RP6530, a novel PI3K d/? dual inhibitor given in combination with an anti-PD-1 therapy, Pembrolizumab in adult patients with relapsed or refractory Classical Hodgkin?s lymphoma (cHL).

Principal Investigator: Ryan Lynch

Study Number: 20181200

Phase: I/II



A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (with and without Bortezomib) in Subjects with Relapsed or Refractory Multiple Myeloma

Principal Investigator: Andrew Cowan

Study Number: 20181226

Phase: I/II



Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC
Complete title: A multicenter, non-randomized, open-label dose escalation Phase Ib study of regorafenib in combination with pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) with no prior systemic therapy

Principal Investigator: William Harris

Study Number: 20181492

Phase: I



Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059
Complete title: PHASE 1 TRIAL OF BC2059 (TEGAVIVINT) IN PATIENTS WITH UNRESECTABLE DESMOID TUMOR

Principal Investigator: Lee Cranmer

Study Number: 20181999

Phase: I



A PHASE 2, MULTICENTER, OPEN-LABEL, 2- COHORT STUDY OF TRASTUZUMAB DERUXTECAN (DS-8201A), AN ANTI-HER2 ANTIBODY DRUG CONJUGATE (ADC), FOR HER2-OVER-EXPRESSING OR -MUTATED, UNRESECTABLE AND/OR METASTATIC NONSMALL CELL LUNG CANCER (NSCLC)

Principal Investigator: Christina Baik

Study Number: 20182077

Phase: II



A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)
Complete title: A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

Principal Investigator: John Thompson, MD

Study Number: 20182093

Phase: I



CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Complete title: A Phase 2, Multicenter, Single-Arm Trial of CV301 in Combination with PD-1/L1 Blockade in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer

Principal Investigator: Petros Grivas, MD, PhD

Study Number: 20182215

Phase: II



A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma (APROMISS)
Complete title: A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma

Principal Investigator: Lee Cranmer

Study Number: 20182495

Phase: III



A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Complete title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

Principal Investigator: Edward Libby

Study Number: 2512.00

Phase: I



Low Dose Cytarabine and Lintuzumab-Ac225 in Older AML Patients
Complete title: A Phase I/II Study of Lintuzumab-Actinium-225 in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Principal Investigator: Johnnie Orozco, MD, PhD

Study Number: 2572.00

Phase: I/II



Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)
Complete title: A Phase III Clinical Trial Evaluating TheraSphere(R) in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Principal Investigator: William Harris

Study Number: 7627

Phase: III



Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia (MIPLATE)
Complete title: Clinical Effectiveness of Standard Versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MIPLATE)

Principal Investigator: Moritz Stolla, MD

Study Number: 9374

Phase: N/A



A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Complete title: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Roland Walter, MD

Study Number: 9382

Phase: I



SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission
Complete title: A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

Principal Investigator: Roland Walter, MD

Study Number: 9498

Phase: I/II



UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease
Complete title: Single-Arm Study to Assess the Efficacy of UVADEX(R) (methoxsalen) Sterile Solution in Conjunction With THERAKOS(R) CELLEX(R) Photopheresis Systems in Pediatric Patients With Steroid-Refractory Acute Graft Versus Host Disease (aGvHD)

Principal Investigator: Paul Carpenter, MD

Study Number: 9550

Phase: III



Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA)
Complete title: IOMAB-01: A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia

Principal Investigator: Johnnie Orozco, MD, PhD

Study Number: 9645

Phase: III



Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
Complete title: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-Assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections that are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Principal Investigator: Joshua Hill

Study Number: 9663

Phase: III



An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Complete title: A Mutli-Center, Open Label, Compassionate Use Extension study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Principal Investigator: Mazyar Shadman

Study Number: 9703

Phase: III



Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Complete title: A Phase 3, Multicenter, Randomized, Open-label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Principal Investigator: Bart Scott, MD

Study Number: 9723

Phase: III



Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation
Complete title: Phase I/II Study of Pembrolizumab in Combination with TG-1101 (Ublituximab) and TGR-1202 in Patients with Relapsed-Refractory CLL or Richter's Transformation of CLL

Principal Investigator: Mazyar Shadman

Study Number: 9727

Phase: I/II



Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL)
Complete title: A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory(R/R) B-cell Non-Hodgkin Lymphoma (NHL)

Principal Investigator: David Maloney, MD, PhD

Study Number: 9734

Phase: I



Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (iNTEGRATE)
Complete title: A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

Principal Investigator: Mary Flowers, MD

Study Number: 9750

Phase: III



A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)
Complete title: A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease

Principal Investigator: Joachim Deeg, MD

Study Number: 9772

Phase: II



Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia
Complete title: An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Principal Investigator: Joachim Deeg, MD

Study Number: 9781

Phase: I



Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE)
Complete title: A Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician's Choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Principal Investigator: Bart Scott, MD

Study Number: 9782

Phase: III



Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)
Complete title: A Randomized, Open-Label, Multi-Center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir versus Foscarnet for the Treatment of Acyclovir-Resistant Mucocutaneous HSV Infections in Immunocompromised Adults (PRIOH-1)

Principal Investigator: Joshua Schiffer, MD

Study Number: 9795

Phase: II



A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Complete title: An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses Of BTCT4465A as a Single Agent and Combined with Atezolizumab in Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Principal Investigator: Mazyar Shadman

Study Number: 9837

Phase: I



Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies
Complete title: An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies

Principal Investigator: Damian Green, MD

Study Number: 9847

Phase: II



Dose-Finding Study of Pacritinib in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib
Complete title: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated with Ruxolitinib

Principal Investigator: Bart Scott, MD

Study Number: 9866

Phase: II



A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)
Complete title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (INHL)

Principal Investigator: David Maloney, MD, PhD

Study Number: 9876

Phase: II



Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Complete title: A Phase 3, Multi-Center Open-Label Randomized Study of Oral Asciminib versus Bosutinib in Patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated with 2 or More Tyrosine Kinase Inhibitors

Principal Investigator: Vivian Oehler, MD

Study Number: 9893

Phase: III



A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Complete title: A Phase III Randomized Open-Label Multi-Center Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogeneic Stem Cell Transplantation (REACH 3)

Principal Investigator: Mary Flowers, MD

Study Number: 9896

Phase: III



A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL
Complete title: An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Principal Investigator: Mazyar Shadman

Study Number: 9905

Phase: III



Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Hematologic Malignancies
Complete title: Infusion of Off the Shelf ex vivo Expanded Cryopreserved Progenitor Cells (NLA101) in the Setting of Single Cord Blood Transplantation for Patients with Hematologic Malignancies

Principal Investigator: Filippo Milano

Study Number: 9910

Phase: II



Safety, Tolerability and Pharmacokinetic Study of K0706
Complete title: A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Principal Investigator: Vivian Oehler, MD

Study Number: 9915

Phase: I/II



A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) (ZUMA-3)
Complete title: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)

Principal Investigator: Ryan Cassaday

Study Number: 9916

Phase: I/II



Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Complete title: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Roland Walter, MD

Study Number: 9919

Phase: I



A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study
Complete title: A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate The Safety, Tolerability And Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years Or Older- The BATTLE Study

Principal Investigator: Roland Walter, MD

Study Number: 9920

Phase: I/II



Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease
Complete title: A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects With Steroid Refractory Chronic Graft versus Host Disease

Principal Investigator: Stephanie Lee, MD, MPH

Study Number: 9926

Phase: I/II



This study is a Phase 2, open-label, 2-cohort, multicenter study evaluating adoptive cell therapy (ACT) with autologous TIL therapy (LN-145) alone, (Cohort 1), or in combination with durvalumab (anti-programmed cell death ligand 1 [PD-L1] monoclonal antibody [mAb]) (Cohort 2).
Complete title: A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination with Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Principal Investigator: Sylvia Lee, MD

Study Number: 9951

Phase: II



Study of AMV564 in Patients With AML
Complete title: A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Principal Investigator: Vivian Oehler, MD

Study Number: 9967

Phase: I



Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease
Complete title: A phase I study of Neihulizumab (AbGn-168H) in patients with steroid-refractory acute graft-versus-host disease (sr-aGvHD)

Principal Investigator: Paul Martin, MD

Study Number: 9978

Phase: I



SEL24 in Patients With AML
Complete title: A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia

Principal Investigator: Roland Walter, MD

Study Number: 9982

Phase: I/II



VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults
Complete title: A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults with Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients

Principal Investigator: Michael Boeckh, MD

Study Number: 9989

Phase: II



A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients (BRIGHT 1012)
Complete title: An Open-Label Phase 1B Study of PF-04449913 (GLASDEGIB) in Combination with AZACITIDINE in Patients with Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Principal Investigator: Vivian Oehler, MD

Study Number: 9995

Phase: I/II



Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Complete title: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Principal Investigator: Julie Park, MD

Study Number: ADVL1711

Phase: I/II



Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)
Complete title: ADVL1722, A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)

Principal Investigator: Julie Park, MD

Study Number: ADVL1722

Phase: I/II



Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
Complete title: A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Principal Investigator: Pamela Becker, MD, PhD

Study Number: RG1018004

Phase: III



A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects
Complete title: SC-4003, BRF116013, Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF V600-Mutation Positive Solid Tumors

Principal Investigator: Sarah Leary

Study Number: SC-4003

Phase: I/II



A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Complete title: SC-4005: A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)

Principal Investigator: Navin Pinto, MD

Study Number: SC-4005

Phase: I/II



A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
Complete title: SC-4007,EZH-102, A Phase I Study of the EZH2 Inhibitor Tazemtostat in Pediatric Subjects with Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Principal Investigator: Navin Pinto, MD

Study Number: SC-4007

Phase: I



A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma
Complete title: SC-4008, EZH-202, A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

Principal Investigator: Erin Pinto

Study Number: SC-4008

Phase: II



Post-Marketing Assessment of Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients
Complete title: SC-4011, A Post-Marketing Study to Further Assess the Immunogenicity and Safety of UnituxinTM in High-Risk Neuroblastoma Patients

Principal Investigator: Julie Park, MD

Study Number: SC-4011

Phase: IV



Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors (SCOUT)
Complete title: SC-4012, LOXO-TRK-15003, Phase I Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients with Advanced Solid or Primary Central Nervous System Tumors

Principal Investigator: Catherine Albert, MD

Study Number: SC-4012

Phase: I



Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
Complete title: SC-4014 A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients with B7-H3-Expressing Relapsed or Refractory Solid Tumors

Principal Investigator: Julie Park, MD

Study Number: SC-4014

Phase: I



A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Complete title: A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and young Adult Patients with Relapsed or Refractory Malignancies.

Principal Investigator: Todd Cooper

Study Number: SC-4015

Phase: I



Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers
Complete title: A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pedicatric Subjects with Previously treated NTRK Fusion Cancers

Principal Investigator: Catherine Albert, MD

Study Number: SC-4016

Phase: I



A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Complete title: A Phase 1, Open-Label, Dose-Escalation Study ofOlaratumab as a Single Agent and in Combination withDoxorubicin, Vincristine/Irinotecan, or High-DoseIfosfamide in Pediatric Patients with Relapsed orRefractory Solid Tumors

Principal Investigator: Doug Hawkins, MD

Study Number: SC-6017

Phase: I



Search all clinical trials

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials